Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Checkpoint Inhibitor Development in Oncology and Autoimmune Diseases.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTPS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTPS1 Wild-Type & Mutant Recombinant Protein High purity (>95%), E. coli/HEK293 expressed. Sequence Verified. Active site variants available (e.g., G146A-equivalent). |
View CTPS1 Products |
| Gene Delivery | CTPS1 ORF Clone / Lentivirus Full-length ORF for stable cell line construction. Endotoxin Controlled. |
View CTPS1 Products |
| Benchmark Ab/Assay Control | Anti-CTPS1 Reference Antibody Recombinant positive control for Western Blot and ELISA. Sequence Verified. |
View CTPS1 Products |
| Validator | CTPS1 siRNA Set (3 unique sequences) For knockdown and rescue experiments. Sequence Verified. |
View CTPS1 Products |
| Isoform Counterscreen | CTPS2 For selectivity profiling vs. housekeeping isoform. High Purity (>95%), Sequence Verified by Mass Spec. |
View CTPS2 Products |
| Pathway Partner A | IMPDH2 Parallel purine synthesis pathway target for combination therapy. |
View IMPDH2 Products |
| Pathway Partner B | CAD (Multifunctional de novo pyrimidine synthesis) Upstream enzyme for combination studies. |
View CAD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (CTPS1 vs CTPS2) | Purified Human CTPS1 and CTPS2 proteins (>95% purity, distinct sequences verified by Mass Spec). |
| Functional Enzymatic Assays | Native conformation preserved through optimized expression systems, yielding theoretical MW without aggregation. |
| Drug Resistance Screening | Active site mutant panel (e.g., G146A-equivalent, ATP/UTP binding site variants) – Sequence Verified, Theoretical MW confirmed. |
| Cellular Context Validation | Lentivirus particles for stable CTPS1-overexpressing cell lines (HEK293, Jurkat compatible). |
| Off-target Metabolic Liability | DHODH, UMPS recombinant proteins available for pathway selectivity panels. |
| Lack of Controls | Recombinant positive control antibodies included for benchmarking. |
| False Positives in Cellular Assays | Validated siRNA included for specificity checks and genetic knockdown validation. |
Live CTPS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CTPS1 therapeutics is intensifying. CTPS1 is a critical metabolic checkpoint in de novo CTP synthesis, essential for rapidly dividing T-cells and certain cancer subsets. Because CTPS1 is required for lymphocyte proliferation while other tissues rely on CTPS2, selective inhibition offers a unique therapeutic window. As first-wave inhibitors (led by Step Pharma's STP938) enter Phase I for relapsed/refractory T- and B-cell lymphomas, the field is pivoting toward autoimmune applications (SLE, RA, multiple sclerosis) and combination regimens with DHODH inhibitors. Major players like Bayer and academic consortia are also pursuing active-site and allosteric small molecules, while emerging biotechs are exploring PROTACs for resistant lymphomas. Future research will focus on overcoming resistance mechanisms (e.g., substrate competition) and expanding into broad autoimmune indications with optimized safety profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Active Site) | Step Pharma, Bayer, Academic Consortia | Lymphoma, Autoimmune Diseases, Graft vs Host Disease | Enzymatic Inhibition Assay (Need WT vs Mutant CTPS1; High-Purity CTPS1 & CTPS2 for selectivity) |
| Small Molecule (Allosteric) | Emerging Biotech | Solid Tumors (metabolic vulnerability) | Conformational Stability Assay, Cross-species orthologs |
| Targeted Protein Degraders (PROTACs) | Preclinical Stage | Refractory Hematological Cancers, Resistant Lymphomas | Binary Interaction Assay (Target/POI vs E3 ligase), Cell penetration validation |